Viking Therapeutics Plans Offering of Common Shares, Senior Notes due 2032

05:19 PM EDT, 09/23/2026 (MT Newswires) -- Viking Therapeutics (VKTX) said late Wednesday it plans separate public offerings of $200 million of its common stock and $200 million of convertible senior notes due 2032. The company will grant the underwriters of the respective offerings a 30-day overallotment option to buy up to an additional $30 million of the shares and notes each, according to a statement. Net proceeds from the offerings will be used for clinical development and commercialization of its VK2735 and VK3019 programs, and for general corporate purposes, the company said.